CVU vs RTX

CVU exhibits severe fundamental deterioration, highlighted by a critical Piotroski F-Score of 0/9, indicating failure across all health benchmarks. While the stock has seen a 50% price surge over the last six months, this momentum is decoupled from financial reality, as both revenue and earnings growth are deeply negative. The company maintains a healthy liquidity position (Current Ratio 1.89), but negative profit margins and a lack of growth suggest a value trap. The deterministic health scores signal high risk despite a low Price-to-Sales ratio.

RTX exhibits stable financial health with a Piotroski F-Score of 5/9, yet it is trading at a severe premium compared to its Graham Number ($73.73) and Intrinsic Value ($96.67). While the company boasts an exceptional track record of earnings beats over 25 quarters and solid revenue growth, the valuation is stretched with a PEG ratio of 2.75. This fundamental overvaluation is compounded by bearish insider sentiment and a weak technical trend, suggesting that while the business is strong, the stock price is currently decoupled from its deterministic value.